Market Place
Sourcing Support
MC2 Therapeutics Gets FDA Feedback, Updates Indication Expansion Plan
13 May 2024 //
GLOBENEWSWIRE
Hyphens Pharma licenses Wynzora Cream for ASEAN countries from MC2 Therapeutics
12 Mar 2024 //
PR NEWSWIRE
MC2 Therapeutics to Present at Upcoming Conferences
26 Feb 2024 //
GLOBENEWSWIRE
MC2 Announces Completion of Enrollment in MC2-25 Ph2 Chronic Kidney Disease
07 Dec 2023 //
GLOBENEWSWIRE
MC2 Announces First Patients Enrolled in Ph 2 Trial in Vulvar Lichen Sclerosus
23 Nov 2023 //
GLOBENEWSWIRE
MC2 Therapeutics Announces Positive Phase 2a Results of Novel HSP90 Inhibitor
11 Oct 2023 //
GLOBENEWSWIRE
Danish biotech gears up for Phase IIb hidradenitis suppurativa trial
11 Oct 2023 //
ENDPTS
EPI & MC2 Announce Data from Survey Conducted by National Psoriasis Foundation
21 Oct 2022 //
GLOBENEWSWIRE
MC2 Therapeutics doses first subjects in Phase II CKD-aP drug trial
16 Sep 2022 //
CLINICALTRIALSARENA
EPI Health, a Novan Company, and MC2 Therapeutics Present WYNZORA®
15 Sep 2022 //
GLOBENEWSWIRE
MC2 Therapeutics announces initiation of a Phase 2 clinical trial in CKD-aP
14 Sep 2022 //
PRNEWSWIRE
MC2 announces breakthrough discovery to help people suffering from skin diseases
01 Sep 2022 //
PRNEWSWIRE
Professor Lars Iversen joins MC2 Therapeutics as new CMO
09 Jun 2022 //
PRNEWSWIRE
EPI Health and MC2 Therapeutics announces U.S. Launch of Wynzora® Cream
19 Jul 2021 //
PR NEWSWIRE
Almirall & MC2 Therapeutics enter a License, Collaboration Commercialization
16 Feb 2021 //
BUSINESSWIRE
MC2 Therapeutics Announces Collaboration Agreement with EPI Health
24 Aug 2020 //
PRESS RELEASE
MC2 Therapeutics Announces FDA Approval of Wynzora® Cream
21 Jul 2020 //
B3CNEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.